Presentations | Sutro Biopharma, Inc.

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Events, News, Presentations, Press Releases

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 – Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and...

65th American Society of Hematology Annual Meeting and Exposition – Poster

Events, News, Presentations

65th American Society of Hematology Annual Meeting and Exposition – Poster Anti-leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBFA2T3::GLIS2 AML ...

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit SOUTH SAN FRANCISCO, Calif., December 4, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Piper Sandler 35th Annual Healthcare Conference – Presentation

Events, News, Presentations

Piper Sandler 35th Annual Healthcare Conference – Presentation...

ESMO Congress 2023 – Presentation

News, Presentations

ESMO Congress 2023 – Presentation Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion...

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 – Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage...

« Older Entries

Next Entries »